Platelet inhibitors versus anticoagulants for prevention of aorto-coronary bypass graft occlusion.

The effects of the antiaggregant substance ticlopidine and of the anticoagulant acenocoumarol on patency rates of aorto-coronary bypass grafts were compared in a prospective randomized trial. Ticlopidine, 250 mg b.i.d. was administered orally from the first postoperative day till angiography, while anticoagulation with acenocoumarol was initiated on the second to third postoperative day. Side-effects of ticlopidine were rare and patient management with the standard dosage of this drug was easier than oral anticoagulation. From an initial group of 166 randomized patients 149 completed the trial by coronary angiography three months postoperatively. The 78 patients in the ticlopidine group showed a compliance of 85%. The average prothrombin time in the 71 patients receiving acenocoumarol was 26.9%. Detailed statistical analysis of the two study groups revealed no reason to doubt the correctness of randomization. Coronary angiography showed an average patency rate per patient of 84% with ticlopidine and of 82% with acenocoumarol. This and various other measures of graft occlusion did not reveal any substantial difference in graft patency of patients receiving ticlopidine or acenocoumarol. It is concluded that ticlopidine may well be used instead of anticoagulants for prevention of postoperative occlusion of aorto-coronary bypass grafts.

[1]  P. Weber,et al.  IMPROVED AORTOCORONARY BYPASS PATENCY BY LOW-DOSE ASPIRIN (100 mg DAILY) Effects on Platelet Aggregation and Thromboxane Formation , 1984, The Lancet.

[2]  P. Rigo,et al.  Effect of ticlopidine on saphenous vein bypass patency rates: a double-blind study. , 1984, The Annals of thoracic surgery.

[3]  V. Fuster,et al.  Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. , 1984, The New England journal of medicine.

[4]  V. Fuster,et al.  A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. , 1982, The New England journal of medicine.

[5]  H. Baur,et al.  Effects of sulfinpyrazone on early graft closure after myocardial revascularization. , 1982, The American journal of cardiology.

[6]  J. Schoevaerdts,et al.  Prevention by Ticlopidine of Platelet Consumption During Extracorporeal Circulation for Heart Surgery and Lack of Effect on Operative and Postoperative Bleeding , 1981, Journal of cardiovascular pharmacology.

[7]  M. Schmuziger,et al.  Improved Graft Patency with Anticoagulant Therapy After Aortocoronary Bypass Surgery: A Prospective, Randomized Study , 1981, Circulation.

[8]  R. Bianco,et al.  Reduction of thrombosis in canine coronary bypass vein grafts with dipyridamole and aspirin. , 1981, The American journal of cardiology.

[9]  E J P Brommer.  The Effect of Ticlopidine upon Platelet Function, Haemorrhage and Post-Operative Thrombosis in Patients Undergoing Suprapubic Prostatectomy , 1981, The Journal of international medical research.

[10]  J. Mayer,et al.  Influence of aspirin and dipyridamole on patency of coronary artery bypass grafts. , 1981, The Annals of thoracic surgery.

[11]  J. Roth,et al.  Improved graft patency with antiplatelet drugs in patients treated for one year following coronary bypass surgery , 1981 .

[12]  V. Fuster,et al.  Noninvasive Radioisotopic Technique for Detection of Platelet Deposition in Coronary Artery Bypass Grafts in Dogs and Its Reduction with Platelet Inhibitors , 1979, Circulation.

[13]  S. Rahimtoola,et al.  Failure of antiplatelet and anticoagulant therapy to improve patency of grafts after coronary-artery bypass: a controlled, randomized study. , 1979, The New England journal of medicine.

[14]  E. Michelson,et al.  Aspirin- and coumadin-related bleeding after coronary- artery bypass graft surgery. , 1978, Annals of internal medicine.

[15]  W. Henry,et al.  Delayed cardiac tamponade associated with prophylactic anticoagulation in patients undergoing coronary bypass grafting. Early diagnosis with two-dimensional echocardiography. , 1978, The Journal of thoracic and cardiovascular surgery.

[16]  G. Hutchins,et al.  Accelerated “Atherosclerosis” A Morphologic Study of 97 Saphenous Vein Coronary Artery Bypass Grafts: A Morphologic Study of 97 Saphenous Vein Coronary Artery Bypass Grafts , 1977, Circulation.

[17]  G. Lawrie,et al.  Vein graft patency and intimal proliferation after aortocoronary bypass: early and long-term angiopathologic correlations. , 1976, The American journal of cardiology.

[18]  J. Blanchard,et al.  Effects of ticlopidine, a new platelet aggregation inhibitor in man , 1975, Clinical pharmacology and therapeutics.

[19]  R. Frye,et al.  Pathologic changes in aortocoronary saphenous vein grafts. , 1974, The American journal of cardiology.

[20]  W. C. Sheldon,et al.  Vein Graft Surgery for Coronary Artery Disease: Survival and Angiographic Results in 1,000 Patients , 1973, Circulation.

[21]  M. Bourassa,et al.  Factors influencing patency of aortocoronary vein grafts. , 1972, Circulation.

[22]  C. Friedberg.  SYMPOSIUM: Myocardial Infraction 1972 (Part 1) Introduction , 1972 .

[23]  J. Edwards,et al.  Pathologic Changes in Aortic‐Coronary Arterial Saphenous Vein Grafts , 1971, Circulation.

[24]  R. Roncucci,et al.  Ticlopidine: a promise for the prevention and treatment of thrombosis and its complications. , 1983, Haemostasis.

[25]  S. Gates,et al.  The effect of antithrombotic therapy on patency rates of saphenous vein coronary artery bypass grafts. , 1982, The Journal of thoracic and cardiovascular surgery.